Biogen Inc(BIIB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:09 PM ET (Korea 10/27 05:09)
Full metrics table
| Index | S&P 500 | P/E | 44.67 | EPS (ttm) | 5.65 | Insider Own | 0.75% | Shs Outstand | 147.7M | Perf Week | 8.04% |
| Market Cap | 37.27B | Forward P/E | 15.37 | EPS next Y | 32.95% | Insider Trans | -0.11% | Shs Float | 146.6M | Perf Month | 10.83% |
| Enterprise Value | 44.34B | PEG | 2.28 | EPS next Q | 1.98 | Inst Own | 98.74% | Short Float | 4.07% | Perf Quarter | 22.69% |
| Income | 0.83B | P/S | 3.86 | EPS this Y | -19.23% | Inst Trans | 3.09% | Short Ratio | 5.79 | Perf Half Y | 39.62% |
| Sales | 9.66B | P/B | 1.98 | EPS next 5Y | 6.74% | ROA | 2.76% | Short Interest | 5.97M | Perf YTD | 43.34% |
| Book/sh | 127.61 | P/C | 29 | EPS past 3/5Y | -25.04% -18.74% | ROE | 4.58% | 52W High | -0.85% ($254.41) | Perf Year | 68.3% |
| Cash/sh | 8.7 | P/FCF | 13.82 | Sales past 3/5Y | 0.35% -5.06% | ROIC | 3.16% | 52W Low | 82.8% ($138.00) | Perf 3Y | 4.64% |
| Dividend Est. | - | EV/EBITDA | 16.26 | EPS Y/Y TTM | -45.79% | Gross Margin | 64.29% | Volatility(W/M) | 3.14% 2.76% | Perf 5Y | -6.96% |
| Dividend TTM | - | EV/Sales | 4.59 | Sales Y/Y TTM | 0.53% | Oper. Margin | 19.5% | ATR (14) | 6.8 | Perf 10Y | -7.62% |
| Dividend Ex-Date | - | Quick Ratio | 1.26 | EPS Q/Q | -84.85% | Profit Margin | 8.64% | RSI (14) | 71.51 | Recom | 1.84 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | 2.38% | SMA20 | 8.69% ($232.09) | Beta | 0.11 | Target Price | $247.55 |
| Payout | - | Debt/Eq | 0.44 | Earnings | 2026/10/28 | SMA50 | 12.5% ($224.23) | Rel Volume | 0.93 | Prev Close | $250.69 |
| Employees | 7500 | LT Debt/Eq | 0.4 | EPS/Sales Surpr. | 22.49% 11.2% | SMA200 | 26.27% ($199.78) | Avg Volume(3M) | 1.03M | Price | $252.26 |
| IPO | 1991/9/17 | Option/Short | Yes/Yes | Trades | 16693 | Volume | 958,806 | Change | 0.63% |
🧠 This is a global pharmaceutical company specializing in the development of treatments for multiple sclerosis, Alzheimer's disease, and rare neurological disorders. Leveraging its long-accumulated R&D capabilities and biopharmaceutical manufacturing expertise, the company has built a strong position in the field of neurological diseases.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded about as much as usual. That is 93% of its average volume.
Next earnings report: October 28
1 days to go.
BIIB earns at a steady pace
Of every $100 in sales, $19.50 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -19.2% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,626. Peers typically go for $1,476. Compared with its own 5-year average, it is 47% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -7.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 98.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #14 of 21 in the industry
Based on market cap of $37B.
FAQ
What kind of company is BIIB?
BIIB belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of BIIB?
The market cap of BIIB is approximately $37.3B, ranking 397 within its sector.
What is the P/E ratio of BIIB?
BIIB has a P/E ratio of approximately 44.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BIIB?
BIIB has recorded a 52-week high of $254.41 and a low of $138.00.
